DalsnaFinance › Analyst accuracy › Jefferies › AMGN target
Jefferies raises Amgen stock price target on drug trial success By Investing.com
Amgen Inc (AMGN) common stock rose 3.29% to $406.09 after Jefferies raised its price target to $410 from $367.
A fact about what Jefferies published, as reported by Investing.com South Africa, not a recommendation from Dalsna Finance; Jefferies is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.